MNOV vs AQST โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
MNOV Captures Institutional Edge (3โ1 Pillars ยท 5โ5 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Medicinova, Inc. (MNOV) driven by superior Valuation, Momentum & Technical, Options & Structure while AQST counters with relative strength in Growth & Margin. Fundamentally, MNOV trades at 8.5x Forward P/E with -1232.2% operating margin (+12.4% YoY revenue) versus AQST at N/M Forward P/E and -114.1% operating margin (-41.0% YoY). In options structure, MNOV sits in UNCLASSIFIED (50th %ile IV; Dealer Gamma Walls on Pro) against AQST sits in BREAKDOWN (64th %ile IV; Dealer Gamma Walls on Pro).
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | MNOV Revenue | AQST Revenue | MNOV Op. Margin | AQST Op. Margin | Margin Edge |
|---|---|---|---|---|---|
| FY2018 | N/A | $70M | N/A | -72.6% | AQST |
| FY2019 | N/A | $50M | N/A | -100.1% | AQST |
| FY2020 | N/A | $50M | N/A | -93.6% | AQST |
| FY2021 | $0M | $50M | -253.0% | -68.2% | AQST |
| FY2022 | N/A | $50M | N/A | -88.2% | AQST |
| FY2023 | $0M | $50M | -990.0% | -29.9% | AQST |
| FY2024 | N/A | $60M | N/A | -53.5% | AQST |
| FY2025 | $0M | $40M | -3242.5% | -159.5% | AQST |
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | MNOV | AQST | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $65.1M | $465.7M | Larger Scale | AQST |
| Trailing P/E Ratio Valuation | 8.5x | N/M | Lower Multiple | MNOV |
| Forward P/E Ratio Valuation | 8.5x | N/M | Lower Multiple | MNOV |
| Revenue Growth (YoY) Growth | +12.4% | -41.0% | Higher Growth | MNOV |
| Operating Margin (TTM) Profitability | -1232.2% | -114.1% | Higher Margin | AQST |
| Net Profit Margin Profitability | 0.0% | -162.3% | Higher Margin | MNOV |
| Return on Equity (ROE) Capital Efficiency | -24.8% | 0.0% | Higher ROE | AQST |
| 52-Week Range Position Momentum | 3% ($1โ$4) | 14% ($3โ$7) | Stronger Trend | AQST |
| Beta / 30D Volatility Risk Regime | 0.59ฮฒ ยท 38% Vol | 0.89ฮฒ ยท 56% Vol | Lower Realized Risk | MNOV |
| Unified Institutional Score Composite Signal | 50.2 / 100 (HOLD) | 62.9 / 100 (BUY) | Higher Composite | AQST |